Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00515_DB06772_nanopub.RANf9bGwr3l8-5kWEe769pWFa5sqWo7nqiNNVBZ1796w0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00515_DB06772 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00515_DB06772 label "DDI between Cisplatin and Cabazitaxel - Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as cabazitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity.Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent. [drugbank_resource:DB00515_DB06772]" assertion.
- drugbank_resource:DB00515_DB06772 identifier "drugbank_resource:DB00515_DB06772" assertion.
- drugbank_resource:DB00515_DB06772 title "DDI between Cisplatin and Cabazitaxel - Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as cabazitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity.Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent." assertion.
- drugbank:DB00515 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00515_DB06772 assertion.
- drugbank:DB06772 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00515_DB06772 assertion.